Immunic Inc (IMUX)

[stockguard]

IMUX Immunic shares a 'bargain' ahead of 'derisking catalysts,' says Roth Capital
Roth Capital analyst Zegbeh Jallah keeps a Buy rating on Immunic with a $64 price target following the company's Q4 report. Immunic has "several derisking catalysts" during 2021, beginning with data in late March or early April from a new dose cohort of IMU-838 in relapsing-remitting multiple sclerosis to support a successful end-of-Phase 2 meeting and Phase 3 study start in the second half of the year, Jallah tells investors in a research note. Data from IMU-838, IMU-935 and IMU-856 "could support a higher valuation for a stock already trading at a bargain," says Jallah. The analyst believes current valuation levels offer a "nice entry point."